On this page
- What retina billing involves
- Who this affects
- Common codes and what they usually mean
- Drug units, wastage, and buy-and-bill
- Units and wastage
- Buy-and-bill vs specialty pharmacy
- Prior authorization and frequency
- Common denial patterns
- Investigation steps when claims go unpaid
- How Mednex works with retina practices
- Mednex and practice responsibilities
- Records and access needed
- Quality checks and exceptions
- How progress is measured
- What cannot be promised
- Sources to verify
- Frequently asked questions
- What do retina billing services include?
- How is this different from general ophthalmology billing?
- What are the JW and JZ modifiers?
- Why do anti-VEGF injections get denied?
- What is buy-and-bill?
- How is retina billing priced?
- Next steps
What retina billing involves
A retina visit often includes imaging, an injection or a surgical procedure, and a high-cost drug. Billing it means pairing the procedure with the correct drug code, reporting the exact number of units administered, reporting any discarded drug with the right wastage modifier, applying laterality, and confirming the payer authorized the drug. Because the drugs are expensive and paid under the medical benefit, the margin for error is financial, not just administrative. General ophthalmology billing is covered on the ophthalmology billing page; this page is specific to the medical and surgical retina work where drug and procedure billing dominate.
Who this affects
Retina specialists, vitreoretinal surgeons, and ophthalmology groups with a retina service line. These are the claims where drug-unit and wastage errors repeat at high dollar value, and where a buy-and-bill inventory model means the practice carries the cost of the drug until the claim pays. A recurring habit — wrong units, missing wastage modifier, missing authorization — compounds quickly.
Common codes and what they usually mean
Confirm current descriptors, drug codes, and payer policy before billing; this is orientation.
- 67028 — intravitreal injection of a pharmacologic agent.
- 67040 / 67042 / 67043 — vitrectomy procedures with varying components.
- 92134 — optical coherence tomography (OCT) of the retina.
- Anti-VEGF drug J-codes — the injectable agents, each billed by exact units (for example aflibercept, ranibizumab, and compounded bevacizumab have their own codes and unit definitions).
- Modifiers JW / JZ — drug wastage reporting: JW for discarded units, JZ attesting no discarded amount.
- RT / LT and other laterality modifiers — required where the payer distinguishes the eye.
The procedure, the drug code, the exact units, the wastage modifier, and laterality all have to be correct and consistent on the same claim.
Drug units, wastage, and buy-and-bill
Units and wastage
Drugs are billed by defined units, and when a single-use vial leaves a discarded amount, that wastage is reported with the JW modifier (or JZ when there is none). Payers audit wastage closely, and both over- and under-reporting cause problems. The units billed have to match the drug administered and the vial size.
Buy-and-bill vs specialty pharmacy
Many retina drugs are bought and billed by the practice (carried as inventory and billed under the medical benefit), while some payers require specialty-pharmacy sourcing. The billing path differs, and billing a buy-and-bill drug for a patient whose plan requires specialty pharmacy is a denial. Knowing each payer’s requirement before the injection matters.
Prior authorization and frequency
Anti-VEGF drugs frequently require prior authorization, and payers apply frequency and step-therapy rules — which drug can be used first, how often injections are covered, and what documentation supports continued treatment. An injection given outside the authorized drug, frequency, or indication denies, and because the drug is already administered, the practice carries the loss. Authorization and frequency tracking before each injection is central.
Common denial patterns
- Drug-unit errors — units not matching the drug and vial administered.
- Wastage modifier errors — JW/JZ missing or inconsistent with the units.
- Missing authorization or step therapy — drug not authorized or not the payer-preferred agent.
- Frequency — injection exceeding the covered interval.
- Laterality — eye modifier missing or wrong.
- Sourcing — buy-and-bill drug billed where specialty pharmacy was required.
Investigation steps when claims go unpaid
The check runs in order: confirm the drug was authorized and is the payer-preferred agent within the covered frequency; confirm units and wastage (JW/JZ) match the vial; confirm laterality; confirm the sourcing path (buy-and-bill vs specialty pharmacy); then review the procedure and imaging codes. Retina denials concentrate in drug units, wastage, and authorization, so those come first.
How Mednex works with retina practices
Mednex manages drug authorization and frequency before injections, bills the procedure and drug with exact units and the correct wastage modifier, applies laterality, confirms the sourcing path, and works the drug-unit and medical-necessity denials. Denials are worked to root cause and the practice gets reporting on denial reasons and on drug-cost exposure in A/R. Mednex works inside the existing EHR and ophthalmology practice-management system.
Mednex and practice responsibilities
Mednex does not administer drugs, decide clinical treatment, or manage drug inventory. Mednex secures authorization, bills the drug and procedure accurately, and works denials. The practice owns the clinical care, the drug administration, and the inventory. Mednex is not a law firm; drug-coverage disputes that become legal matters are for the practice’s counsel.
Records and access needed
- Access to the EHR and ophthalmology practice-management system.
- Injection records with drug, units, vial size, and eye documented.
- Authorization records and each payer’s preferred-drug and frequency rules.
- Sourcing details (buy-and-bill vs specialty pharmacy) by payer.
- The payer mix and relevant drug coverage policies.
No protected health information is collected through this website. When records are needed, they move through a secure workflow under a signed business associate agreement.
Quality checks and exceptions
Before submission, claims are checked for authorization, drug-unit and wastage accuracy, laterality, and sourcing. Exceptions — a switch between drugs, a frequency near the limit, a specialty-pharmacy requirement — are flagged for review before the injection where possible.
How progress is measured
Performance is measured on clean-claim rate, drug-unit and wastage accuracy, authorization capture, and drug-cost exposure in aging A/R — not on a revenue promise. These show whether the gap is authorization, units, or sourcing.
What cannot be promised
- That a payer will authorize or cover a given drug or injection frequency.
- That a specific amount of revenue will result.
- That a drug given outside authorization or sourcing rules will be paid.
- That a frequency or step-therapy denial will overturn on appeal.
Sources to verify
Retina drug codes, units, wastage rules, and coverage change. Before relying on any statement here for a claim, verify against current primary sources: the Medicare Physician Fee Schedule and ASP drug pricing files, CMS JW/JZ wastage guidance, the CMS Medicare Coverage Database, and the specific payer’s drug and authorization policy.
Frequently asked questions
What do retina billing services include?
Drug authorization and frequency management before injections, billing the procedure and drug with exact units and the correct wastage modifier, applying laterality, confirming the sourcing path, and working drug-unit and medical-necessity denials.
How is this different from general ophthalmology billing?
General ophthalmology billing covers exams, cataract, and routine eye care; retina billing is dominated by high-cost injectable drugs billed by exact units with wastage modifiers under the medical benefit, plus vitreoretinal surgery, which carries different and higher-stakes rules.
What are the JW and JZ modifiers?
JW reports discarded drug (wastage) from a single-use vial, and JZ attests that no amount was discarded. Payers audit these closely, and they must be consistent with the units billed.
Why do anti-VEGF injections get denied?
Common reasons are missing authorization, not using the payer-preferred drug under step therapy, exceeding the covered frequency, wrong drug units, or a sourcing mismatch between buy-and-bill and specialty pharmacy.
What is buy-and-bill?
Buy-and-bill means the practice purchases the drug as inventory and bills it under the medical benefit after administration, carrying the cost until the claim pays. Some payers instead require the drug be sourced through specialty pharmacy, which changes the billing path.
How is retina billing priced?
Pricing depends on injection volume and drug mix. Mednex reviews a sample before proposing scope. Start with a free billing audit.
Next steps
If retina claims deny on drug units, wastage, or authorization — or drug cost sits too long in A/R — a free medical billing audit will show where. Mednex reviews a sample of injection and surgical claims and denials and sends a written summary. No patient information is needed to begin. This pairs with ophthalmology billing, prior authorization, medical billing, and denial management; or contact Mednex.